Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accounts Payables (2018 - 2021)

Historic Accounts Payables for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $4.9 million.

  • Black Diamond Therapeutics' Accounts Payables rose 6572.31% to $4.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $4.9 million, marking a year-over-year increase of 6572.31%. This contributed to the annual value of $2.5 million for FY2020, which is 2922.61% up from last year.
  • Latest data reveals that Black Diamond Therapeutics reported Accounts Payables of $4.9 million as of Q3 2021, which was up 6572.31% from $5.0 million recorded in Q2 2021.
  • In the past 5 years, Black Diamond Therapeutics' Accounts Payables ranged from a high of $5.0 million in Q2 2021 and a low of $45000.0 during Q2 2020
  • For the 4-year period, Black Diamond Therapeutics' Accounts Payables averaged around $2.9 million, with its median value being $2.9 million (2020).
  • Within the past 5 years, the most significant YoY rise in Black Diamond Therapeutics' Accounts Payables was 1107777.78% (2021), while the steepest drop was 2153.77% (2021).
  • Black Diamond Therapeutics' Accounts Payables (Quarter) stood at $416000.0 in 2018, then surged by 372.12% to $2.0 million in 2019, then grew by 29.23% to $2.5 million in 2020, then surged by 91.45% to $4.9 million in 2021.
  • Its last three reported values are $4.9 million in Q3 2021, $5.0 million for Q2 2021, and $4.6 million during Q1 2021.